PMID- 28295515
OWN - NLM
STAT- MEDLINE
DCOM- 20180430
LR  - 20180430
IS  - 1346-8138 (Electronic)
IS  - 0385-2407 (Linking)
VI  - 44
IP  - 8
DP  - 2017 Aug
TI  - Two cases of melanomas paradoxically metastasizing to the intestinal tract during
      nivolumab therapy.
PG  - 959-962
LID - 10.1111/1346-8138.13825 [doi]
AB  - We report two cases of melanomas in patients who developed intestinal metastasis 
      despite other metastatic sites responding to nivolumab and despite the patients
      having favorable findings such as vitiligo and normal lactate dehydrogenase. The 
      first case is an 85-year-old man who had been administrated nivolumab for
      lung/cutaneous metastases. After 22 courses of nivolumab therapy, fever and
      anorexia had appeared and his bodyweight had decreased. An intussusception on the
      ileocecal valve was revealed by computed tomography, and emergency surgery
      revealed metastatic lesions on the colon. The second case is an 87-year-old woman
      treated with nivolumab for lymph node metastases. After 10 courses, laboratory
      tests had revealed anemia and positive fecal occult blood. Her bodyweight had
      decreased. Capsule endoscopy showed scattered tumors and clots, indicating
      metastases of melanoma. The frequency of symptomatic intestinal metastasis of
      melanoma is very low. Further, intestinal metastasis of melanoma is difficult to 
      detect through routine examinations. Our cases suggest that fecal occult blood
      test and decreased bodyweight are indications of intestinal metastases.
CI  - (c) 2017 Japanese Dermatological Association.
FAU - Miyazawa, Hajime
AU  - Miyazawa H
AUID- ORCID: http://orcid.org/0000-0002-0802-1864
AD  - Department of Dermatology, Hokkaido University Graduate School of Medicine,
      Sapporo.
FAU - Yanagi, Teruki
AU  - Yanagi T
AD  - Department of Dermatology, Hokkaido University Graduate School of Medicine,
      Sapporo.
FAU - Yamaguchi, Yasuyuki
AU  - Yamaguchi Y
AD  - Department of Dermatology, Hokkaido University Graduate School of Medicine,
      Sapporo.
FAU - Imafuku, Keisuke
AU  - Imafuku K
AD  - Department of Dermatology, Hokkaido University Graduate School of Medicine,
      Sapporo.
FAU - Kitamura, Shinya
AU  - Kitamura S
AD  - Department of Dermatology, Hokkaido University Graduate School of Medicine,
      Sapporo.
FAU - Hata, Hiroo
AU  - Hata H
AD  - Department of Dermatology, Hokkaido University Graduate School of Medicine,
      Sapporo.
FAU - Uehara, Jiro
AU  - Uehara J
AD  - Department of Dermatology, Asahikawa Medical University, Asahikawa.
FAU - Ichikawa, Nobuki
AU  - Ichikawa N
AD  - Department of Gastroenterological Surgery I, Hokkaido University Graduate School 
      of Medicine, Sapporo, Japan.
FAU - Ohno, Yosuke
AU  - Ohno Y
AD  - Department of Gastroenterological Surgery I, Hokkaido University Graduate School 
      of Medicine, Sapporo, Japan.
FAU - Yoshida, Tadashi
AU  - Yoshida T
AD  - Department of Gastroenterological Surgery I, Hokkaido University Graduate School 
      of Medicine, Sapporo, Japan.
FAU - Homma, Shigenori
AU  - Homma S
AD  - Department of Gastroenterological Surgery I, Hokkaido University Graduate School 
      of Medicine, Sapporo, Japan.
FAU - Kawamura, Hideki
AU  - Kawamura H
AD  - Department of Gastroenterological Surgery I, Hokkaido University Graduate School 
      of Medicine, Sapporo, Japan.
FAU - Taketomi, Akinobu
AU  - Taketomi A
AD  - Department of Gastroenterological Surgery I, Hokkaido University Graduate School 
      of Medicine, Sapporo, Japan.
FAU - Shimizu, Hiroshi
AU  - Shimizu H
AD  - Department of Dermatology, Hokkaido University Graduate School of Medicine,
      Sapporo.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20170311
PL  - England
TA  - J Dermatol
JT  - The Journal of dermatology
JID - 7600545
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 31YO63LBSN (nivolumab)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - C-Reactive Protein/analysis
MH  - Colonic Neoplasms/diagnostic imaging/secondary/*surgery
MH  - Colonoscopy
MH  - Dacarbazine/therapeutic use
MH  - Endoscopy, Gastrointestinal
MH  - Fatal Outcome
MH  - Female
MH  - Humans
MH  - Ileocecal Valve/diagnostic imaging
MH  - Intussusception/diagnostic imaging/etiology
MH  - Lung Neoplasms/diagnostic imaging/*drug therapy/secondary
MH  - Lymphatic Metastasis
MH  - Male
MH  - Melanoma/*drug therapy/pathology
MH  - Occult Blood
MH  - Skin/pathology
MH  - Skin Neoplasms/*drug therapy/pathology
MH  - Tomography, X-Ray Computed
OTO - NOTNLM
OT  - fecal occult blood test
OT  - intestinal metastasis
OT  - malignant melanoma
OT  - nivolumab
OT  - weight loss
EDAT- 2017/03/16 06:00
MHDA- 2018/05/01 06:00
CRDT- 2017/03/16 06:00
PHST- 2016/12/12 00:00 [received]
PHST- 2017/02/01 00:00 [accepted]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2018/05/01 06:00 [medline]
PHST- 2017/03/16 06:00 [entrez]
AID - 10.1111/1346-8138.13825 [doi]
PST - ppublish
SO  - J Dermatol. 2017 Aug;44(8):959-962. doi: 10.1111/1346-8138.13825. Epub 2017 Mar
      11.